The effects of T-DXd on the expression of HLA class I and chemokines CXCL9/10/11 in HER2-overexpressing gastric cancer cells
Abstract Trastuzumab deruxtecan (T-DXd), a HER2-targeting antibody–drug conjugate with a topoisomerase I inhibitor deruxtecan (DXd), exhibits an excellent anti-tumor effect in previously treated HER2-positive tumors. A recent study demonstrated that T-DXd not only suppressed tumor growth but also en...
Guardado en:
Autores principales: | Shotaro Nakajima, Kosaku Mimura, Takuro Matsumoto, Aung Kyi Thar Min, Misato Ito, Hiroshi Nakano, Prajwal Neupane, Yasuyuki Kanke, Hirokazu Okayama, Motonobu Saito, Tomoyuki Momma, Yohei Watanabe, Hiroyuki Hanayama, Suguru Hayase, Zenichiro Saze, Koji Kono |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/5863079157eb48a886f17c4d0fc1a7f2 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
PD-L1 overexpression in EBV-positive gastric cancer is caused by unique genomic or epigenomic mechanisms
por: Hiroshi Nakano, et al.
Publicado: (2021) -
Functional benefits of the double flap technique after proximal gastrectomy for gastric cancer
por: Zenichiro Saze, et al.
Publicado: (2021) -
Spotlight on Trastuzumab Deruxtecan (DS-8201,T-DXd) for HER2 Mutation Positive Non-Small Cell Lung Cancer
por: Azar I, et al.
Publicado: (2021) -
Human brain metastatic stroma attracts breast cancer cells via chemokines CXCL16 and CXCL12
por: Brile Chung, et al.
Publicado: (2017) -
Serotonin-mediated tuning of human helper T cell responsiveness to the chemokine CXCL12.
por: Elena Magrini, et al.
Publicado: (2011)